|
GB8311018D0
(en)
|
1983-04-22 |
1983-05-25 |
Amersham Int Plc |
Detecting mutations in dna
|
|
US4998617A
(en)
|
1986-09-15 |
1991-03-12 |
Laura Lupton Inc |
Facial cosmetic liquid make up kit
|
|
US5202231A
(en)
|
1987-04-01 |
1993-04-13 |
Drmanac Radoje T |
Method of sequencing of genomes by hybridization of oligonucleotide probes
|
|
US6270961B1
(en)
|
1987-04-01 |
2001-08-07 |
Hyseq, Inc. |
Methods and apparatus for DNA sequencing and DNA identification
|
|
US5176996A
(en)
|
1988-12-20 |
1993-01-05 |
Baylor College Of Medicine |
Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use
|
|
US5256775A
(en)
|
1989-06-05 |
1993-10-26 |
Gilead Sciences, Inc. |
Exonuclease-resistant oligonucleotides
|
|
FR2650840B1
(fr)
|
1989-08-11 |
1991-11-29 |
Bertin & Cie |
Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
|
|
US5264564A
(en)
|
1989-10-24 |
1993-11-23 |
Gilead Sciences |
Oligonucleotide analogs with novel linkages
|
|
US5210015A
(en)
|
1990-08-06 |
1993-05-11 |
Hoffman-La Roche Inc. |
Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
|
|
US6004744A
(en)
|
1991-03-05 |
1999-12-21 |
Molecular Tool, Inc. |
Method for determining nucleotide identity through extension of immobilized primer
|
|
US5858659A
(en)
|
1995-11-29 |
1999-01-12 |
Affymetrix, Inc. |
Polymorphism detection
|
|
US5952172A
(en)
|
1993-12-10 |
1999-09-14 |
California Institute Of Technology |
Nucleic acid mediated electron transfer
|
|
US5968740A
(en)
|
1995-07-24 |
1999-10-19 |
Affymetrix, Inc. |
Method of Identifying a Base in a Nucleic Acid
|
|
AU2734197A
(en)
|
1996-04-19 |
1997-11-12 |
Spectra Biomedical, Inc. |
Correlating polymorphic forms with multiple phenotypes
|
|
JP2894445B2
(ja)
|
1997-02-12 |
1999-05-24 |
日本たばこ産業株式会社 |
Ｃｅｔｐ活性阻害剤として有効な化合物
|
|
CA2303206A1
(en)
|
1997-09-10 |
1999-03-18 |
University Of Maryland, Baltimore |
Method of amplifying dna and rna mismatch cleavage products
|
|
US6197786B1
(en)
|
1998-09-17 |
2001-03-06 |
Pfizer Inc |
4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
|
|
EP1187527B2
(en)
|
1999-06-04 |
2010-06-09 |
Consejo Superior de Investigaciones Cientificas |
Use of high oleic high stearic oils
|
|
US20030092647A1
(en)
|
2001-08-08 |
2003-05-15 |
Crooke Rosanne M. |
Antisense modulation of cholesteryl ester transfer protein expression
|
|
CO5271716A1
(es)
|
1999-11-30 |
2003-04-30 |
Pfizer Prod Inc |
Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
|
|
AU2002323270A1
(en)
|
2001-08-18 |
2003-03-03 |
Myriad Genetics, Inc |
Composition and method for treating hiv infection
|
|
US20060141493A1
(en)
|
2001-11-09 |
2006-06-29 |
Duke University Office Of Science And Technology |
Atherosclerotic phenotype determinative genes and methods for using the same
|
|
US20040180370A1
(en)
|
2003-01-27 |
2004-09-16 |
The Regents Of The University Of Colorado, A Body Corporate |
Genetic diagnosis of alcoholism subtypes
|
|
CA2519458A1
(en)
|
2003-03-17 |
2004-09-30 |
Japan Tobacco Inc. |
Method for increasing the oral bioavailability of s-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
|
|
TWI393560B
(zh)
|
2003-05-02 |
2013-04-21 |
Japan Tobacco Inc |
包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
|
|
WO2005007111A2
(en)
|
2003-07-11 |
2005-01-27 |
Bristol-Myers Squibb Company |
Tetrahydroquinoline derivatives as cannabinoid receptor modulators
|
|
US7326706B2
(en)
|
2003-08-15 |
2008-02-05 |
Bristol-Myers Squibb Company |
Pyrazine modulators of cannabinoid receptors
|
|
CN103330703A
(zh)
|
2003-09-26 |
2013-10-02 |
日本烟草产业株式会社 |
抑制残余脂蛋白产生的方法
|
|
US7517900B2
(en)
|
2003-10-10 |
2009-04-14 |
Bristol-Myers Squibb Company |
Pyrazole derivatives as cannabinoid receptor modulators
|
|
US7420059B2
(en)
|
2003-11-20 |
2008-09-02 |
Bristol-Myers Squibb Company |
HMG-CoA reductase inhibitors and method
|
|
KR20060103265A
(ko)
|
2003-12-19 |
2006-09-28 |
브리스톨-마이어스 스큅 컴퍼니 |
카나비노이드 수용체 조절제인 아자비시클릭 헤테로사이클
|
|
ATE360630T1
(de)
|
2003-12-19 |
2007-05-15 |
Bristol Myers Squibb Co |
Azabicyclische heterocyclen als modulatoren des cannabinoidrezeptors
|
|
EP1735055A1
(en)
|
2004-03-30 |
2006-12-27 |
Sapphire Therapeutics, Inc. |
Method of reducing c-reactive protein using growth hormone secretagogues
|
|
DOP2005000123A
(es)
|
2004-07-02 |
2011-07-15 |
Merck Sharp & Dohme |
Inhibidores de cetp
|
|
BRPI0519602A2
(pt)
|
2004-12-18 |
2009-02-25 |
Bayer Healthcare Ag |
derivados de tetrahidroquinolina substituÍdos com 4-cicloalquila e seu uso como medicamento
|
|
AU2006204563A1
(en)
|
2005-01-05 |
2006-07-13 |
Medicure International Inc. |
Compounds and methods for regulating triglyceride levels
|
|
WO2006099142A2
(en)
*
|
2005-03-10 |
2006-09-21 |
The Trustees Of Boston University |
Prognostic method for vascular diseases
|
|
JP2006288279A
(ja)
|
2005-04-11 |
2006-10-26 |
Otsuka Pharmaceut Co Ltd |
出血時間延長傾向判定方法
|
|
JP5112307B2
(ja)
|
2005-07-01 |
2013-01-09 |
メルク・シャープ・エンド・ドーム・コーポレイション |
Ｃｅｔｐ阻害剤を合成するための方法
|
|
KR20080059233A
(ko)
|
2005-10-21 |
2008-06-26 |
노파르티스 아게 |
레닌 억제제, 및 항이상지질혈증제 및/또는 항비만제의조합물
|
|
US7435849B2
(en)
|
2005-10-31 |
2008-10-14 |
Hoffmann-La Roche Inc. |
Process for the production of acid chlorides
|
|
BRPI0618379A2
(pt)
|
2005-11-08 |
2011-08-30 |
Ranbaxy Lab Ltd |
processo para preparação do hemi-sal de cálcio do ácido (3r,5r) -7-[2-(4-fluorofenil)-5-isopropil-3-fenil-4-[(4-hidroxime tilfenilamino) carbonil]-pirrol-1-il] -3, 5-diidroxi heptanóico
|
|
US20070213274A1
(en)
*
|
2005-12-20 |
2007-09-13 |
Oy Jurilab Ltd |
Novel genes and markers associated with high-density lipoprotein-cholesterol (HDL-C)
|
|
PE20080251A1
(es)
|
2006-05-04 |
2008-04-25 |
Boehringer Ingelheim Int |
Usos de inhibidores de dpp iv
|
|
WO2008067219A2
(en)
|
2006-11-29 |
2008-06-05 |
Kalypsys, Inc. |
Quinazolinone modulators of tgr5
|
|
EP1935867A1
(en)
|
2006-12-20 |
2008-06-25 |
F. Hoffmann-La Roche Ag |
Process for preparing 1-(2-ethyl-butyl)-cyclohexanecarboxylic acid
|
|
WO2008097976A1
(en)
|
2007-02-09 |
2008-08-14 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
|
WO2008132044A1
(en)
|
2007-04-25 |
2008-11-06 |
F. Hoffmann-La Roche Ag |
Novel process for the preparation of acid chlorides
|
|
US20090054304A1
(en)
|
2007-08-23 |
2009-02-26 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
|
US20090105124A1
(en)
|
2007-08-23 |
2009-04-23 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5
|
|
WO2009121788A1
(en)
|
2008-04-04 |
2009-10-08 |
F. Hoffmann-La Roche Ag |
New process for the preparatiion of cyclohexanecarboxylic acid dericatives
|
|
JP5526120B2
(ja)
|
2008-04-04 |
2014-06-18 |
エフ．ホフマン−ラ ロシュ アーゲー |
対応するシクロヘキサンカルボキシアミド誘導体を経るシクロヘキサンカルボン酸誘導体の新規な製造方法
|
|
ES2624716T3
(es)
|
2008-06-17 |
2017-07-17 |
F. Hoffmann-La Roche Ag |
Éster del ácido 1-(2-etil-butil)-ciclohexanocarboxílico como intermedio en la preparación de amidas farmacéuticamente activas
|
|
EP2177615A1
(en)
|
2008-10-10 |
2010-04-21 |
Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. |
Method for a genome wide identification of expression regulatory sequences and use of genes and molecules derived thereof for the diagnosis and therapy of metabolic and/or tumorous diseases
|
|
WO2010056910A2
(en)
|
2008-11-12 |
2010-05-20 |
Carolus Therapeutics, Inc. |
Methods of treating cardiovascular disorders
|
|
KR101459181B1
(ko)
|
2008-12-08 |
2014-11-07 |
에프. 호프만-라 로슈 아게 |
병용 약물 투여
|
|
CN102413825A
(zh)
|
2009-04-29 |
2012-04-11 |
阿马里纳股份公司 |
含有epa和心血管剂的药物组合物以及使用其的方法
|
|
TWI450896B
(zh)
|
2009-06-30 |
2014-09-01 |
Lilly Co Eli |
反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
|
|
US20110004011A1
(en)
|
2009-07-01 |
2011-01-06 |
Declan Costello |
Novel process
|
|
JP2012533560A
(ja)
|
2009-07-15 |
2012-12-27 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
細胞における取り込みが制御可能なペプチド
|
|
EP2556159A1
(en)
*
|
2010-04-07 |
2013-02-13 |
Isis Pharmaceuticals, Inc. |
Modulation of cetp expression
|
|
WO2012012870A1
(en)
*
|
2010-07-28 |
2012-02-02 |
Institut De Cardiologie De Montreal |
Pharmaceutical compositions for the treatment of left ventricular diastolic dysfunction comprising an apolipoprotein peptide/phospholipid complex
|
|
WO2012035017A1
(en)
|
2010-09-16 |
2012-03-22 |
F. Hoffmann-La Roche Ag |
New process
|
|
MY164729A
(en)
|
2010-11-04 |
2018-01-30 |
Hoffmann La Roche |
A composition comprising s-[2- ( [ [1- (2-ethylbutyl) - cyclohexyl] - carbonyl]amino)phenyl] 2-methylpropanethioate and croscarmellose sodium
|
|
WO2012069087A1
(en)
|
2010-11-25 |
2012-05-31 |
Mediasuccess Gmbh |
Automatic text generation
|
|
WO2012076443A1
(en)
|
2010-12-08 |
2012-06-14 |
F. Hoffmann-La Roche Ag |
Liposomal formulation of dalcetrapib
|
|
JP6054875B2
(ja)
|
2010-12-16 |
2016-12-27 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
ジスルフィドの水素化による芳香族チオール誘導体の調製方法
|
|
WO2012112720A2
(en)
*
|
2011-02-15 |
2012-08-23 |
The Ohio University Research Foundaton |
Methods for predicting cardiovascular risks and responsiveness to statin therapy using snps
|
|
RU2013139701A
(ru)
*
|
2011-02-17 |
2015-03-27 |
Ф. Хоффманн-Ля Рош Аг |
Способ контролируемой кристаллизации активного фармацевтического ингредиента из состояния переохлажденной жидкости экструзией горячего распада
|
|
US9664698B2
(en)
|
2011-04-08 |
2017-05-30 |
Zora Biosciences Oy |
Biomarkers for sensitive detection of statin-induced muscle toxicity
|
|
US9541565B2
(en)
|
2011-04-08 |
2017-01-10 |
Zora Biosciences Oy |
Biomarkers for sensitive detection of statin-induced muscle toxicity
|
|
WO2012149473A2
(en)
*
|
2011-04-29 |
2012-11-01 |
Children's Hospital & Research Center At Oakland |
Compositions and methods to assess the capacity of hdl to support reverse cholesterol transport
|
|
US20120301439A1
(en)
|
2011-05-24 |
2012-11-29 |
Washington University |
Inhibition of choroidal neovascularization
|
|
US8975438B2
(en)
|
2011-07-13 |
2015-03-10 |
Hoffmann-La Roche Inc. |
Process for the preparation of cyclohexanecarboxylic acid derivatives
|
|
AR089853A1
(es)
|
2012-02-01 |
2014-09-24 |
Boehringer Ingelheim Int |
Inhibidores de oxadiazol de la produccion de leucotrienos para terapia de combinacion, composicion farmaceutica, uso
|
|
CA2866471A1
(en)
|
2012-03-06 |
2013-09-12 |
Boehringer Ingelheim International Gmbh |
Benzodioxanes in combination with other actives for inhibiting leukotriene production
|
|
EP2844245A1
(en)
|
2012-04-30 |
2015-03-11 |
F. Hoffmann-La Roche AG |
New formulation
|
|
MX351059B
(es)
|
2012-08-17 |
2017-09-29 |
Laboratorios Senosiain S A De C V Star |
Composicion farmaceutica oral en forma de microesferas y proceso de elaboracion.
|
|
CN111073974B
(zh)
|
2013-03-27 |
2024-04-09 |
豪夫迈·罗氏有限公司 |
用于预测对于治疗的响应性的遗传标记
|
|
KR20160093024A
(ko)
|
2013-12-19 |
2016-08-05 |
에프. 호프만-라 로슈 아게 |
눈 질환의 치료에 사용하기 위한 cetp 조절제
|
|
GB201401617D0
(en)
*
|
2014-01-30 |
2014-03-19 |
Helperby Therapeutics Ltd |
Novel combination and use
|
|
JP6854752B2
(ja)
|
2014-07-30 |
2021-04-07 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｈｄｌ上昇剤又はｈｄｌ模倣剤を用いた治療に対する応答性を予測するための遺伝マーカー
|
|
WO2019043018A1
(en)
|
2017-08-29 |
2019-03-07 |
Dalcor Pharma Uk Ltd., Stockport Zug Branch |
METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND REDUCING THE RISK OF CARDIOVASCULAR EVENTS
|
|
SG11202101086YA
(en)
|
2018-08-09 |
2021-03-30 |
Dalcor Pharma Uk Ltd Leatherhead |
Methods for delaying occurrence of new-onset type 2 diabetes and for slowing progression of and treating type 2 diabetes
|